Ruweida Mohamed Bundid
Ruweida Mohamed Bundid has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Khaled Hamed
Ondokuz Mayiz University, Turkey (Türkiye)
3 shared publications - Maha Ali Sayah
Ondokuz Mayiz University, Turkey (Türkiye)
3 shared publications - Mohamed Gamal
South Valley University
1 shared publication - Nahid Nuri
Ondokuz Mayiz University
1 shared publication - Rawan Saeed Mohamed Taha
Ondokuz Mayiz University
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by MDPI AG in Preprints.org
Mortality Trends and Disparities Associated with Hepatic Vascular Diseases in the United States, 1999–2024: A CDC WONDER Multiple-Cause-of-Death Analysis
Background: Hepatic vascular diseases (HVDs)—encompassing portal inflow, sinusoidal microcirculatory, hepatic venous outflow, and hepatic arterial disorders—cause severe portal hypertension, liver failure, and death. Despite major therapeutic advances, national long-term mortality trends and demographic disparities across this spectrum of diseases remain undefined. Methods: In this nationwide, population-based serial cross-sectional study, we analyzed CDC WONDER Multiple Cause of Death records for U.S. decedents aged ≥25 years from 1999 through 2024. HVD-related deaths were identified by any mention of primary vascular lesions across the four vascular compartments (ICD-10 codes: I81, K75.1, I82.0, K76.5, K76.4, and K76.3). Age-adjusted mortality rates (AAMRs), standardized to the 2000 U.S. population, and Joinpoint regression models were used to estimate annual percent change (APC) and average annual percent change (AAPC). Results: Among 22,498 HVD-related deaths, annual fatalities increased 4.7-fold, from 433 in 1999 to 2,025 in 2024, while the AAMR rose from 0.233 to 0.735 per 100,000 (overall AAPC, 4.94% [95% CI, 4.60%–5.24%]). Following a decade of relative stability from 1999 to 2011 (APC, 0.85%), mortality underwent a steep upward inflection during 2011–2024 (APC, 8.87% [95% CI, 8.31%–9.52%]). Portal vein thrombosis (PVT) accounted for 80.8% of all deaths (n = 18,189) and increased rapidly (AAPC, 7.48%); notably, excluding PVT abolished the secular upward trend across the remaining HVDs (AAPC, −0.55% [95% CI, −1.62% to 0.60%]). Concurrent mentions of cirrhosis nearly doubled (19.6% to 35.2%), and co-listing of hepatocellular carcinoma more than tripled (6.5% to 20.1%). Persistent disparities were observed: males had higher mortality than females (rate ratio [RR], 1.52; 95% CI, 1.48–1.56), Hispanic individuals bore the highest racial and ethnic burden (AAMR, 0.434), the West had the highest regional mortality rate (AAMR, 0.460), and nonmetropolitan residents experienced excess mortality compared with metropolitan residents (RR, 1.13; 95% CI, 1.08–1.18). Mortality briefly exceeded pre-pandemic projections only in 2021. Conclusions: Mortality from hepatic vascular diseases in the United States has escalated rapidly since 2011, driven primarily by portal vein thrombosis amid increasing national burdens of cirrhosis and liver cancer. Marked sex, racial and ethnic, and rural–urban disparities highlight the urgent need for targeted vascular surveillance and equitable access to specialized multidisciplinary hepatology and endovascular care.
- 1 October 2026
- Published by MDPI AG in Preprints.org
Open AccessMortality Trends and Disparities Associated with Hepatic Vascular Diseases in the United States, 1999–2024: A CDC WONDER Multiple-Cause-of-Death Analysis
Background: Hepatic vascular diseases (HVDs)—encompassing portal inflow, sinusoidal microcirculatory, hepatic venous outflow, and hepatic arterial disorders—cause severe portal hypertension, liver failure, and death. Despite major therapeutic advances, national long-term mortality trends and demographic disparities across this spectrum of diseases remain undefined. Methods: In this nationwide, population-based serial cross-sectional study, we analyzed CDC WONDER Multiple Cause of Death records for U.S. decedents aged ≥25 years from 1999 through 2024. HVD-related deaths were identified by any mention of primary vascular lesions across the four vascular compartments (ICD-10 codes: I81, K75.1, I82.0, K76.5, K76.4, and K76.3). Age-adjusted mortality rates (AAMRs), standardized to the 2000 U.S. population, and Joinpoint regression models were used to estimate annual percent change (APC) and average annual percent change (AAPC). Results: Among 22,498 HVD-related deaths, annual fatalities increased 4.7-fold, from 433 in 1999 to 2,025 in 2024, while the AAMR rose from 0.233 to 0.735 per 100,000 (overall AAPC, 4.94% [95% CI, 4.60%–5.24%]). Following a decade of relative stability from 1999 to 2011 (APC, 0.85%), mortality underwent a steep upward inflection during 2011–2024 (APC, 8.87% [95% CI, 8.31%–9.52%]). Portal vein thrombosis (PVT) accounted for 80.8% of all deaths (n = 18,189) and increased rapidly (AAPC, 7.48%); notably, excluding PVT abolished the secular upward trend across the remaining HVDs (AAPC, −0.55% [95% CI, −1.62% to 0.60%]). Concurrent mentions of cirrhosis nearly doubled (19.6% to 35.2%), and co-listing of hepatocellular carcinoma more than tripled (6.5% to 20.1%). Persistent disparities were observed: males had higher mortality than females (rate ratio [RR], 1.52; 95% CI, 1.48–1.56), Hispanic individuals bore the highest racial and ethnic burden (AAMR, 0.434), the West had the highest regional mortality rate (AAMR, 0.460), and nonmetropolitan residents experienced excess mortality compared with metropolitan residents (RR, 1.13; 95% CI, 1.08–1.18). Mortality briefly exceeded pre-pandemic projections only in 2021. Conclusions: Mortality from hepatic vascular diseases in the United States has escalated rapidly since 2011, driven primarily by portal vein thrombosis amid increasing national burdens of cirrhosis and liver cancer. Marked sex, racial and ethnic, and rural–urban disparities highlight the urgent need for targeted vascular surveillance and equitable access to specialized multidisciplinary hepatology and endovascular care.
- Open Access
National trends, demographic disparities, and phenotypic shifts in encephalopathy-associated mortality in the United States: A CDC WONDER analysis, 1999-2024
Encephalopathy is a lethal manifestation of global cerebral dysfunction spanning hypoxic, metabolic, toxic, and vascular etiologies, yet its population burden is difficult to quantify because it predominantly appears as a contributing rather than underlying cause of death. Here, we analyzed US multiple-cause death records from 1999 through 2024 using harmonized CDC WONDER datasets. A longitudinally consistent core definition of 10 ICD-10 codes identified 953,846 encephalopathy-associated deaths. The national age-adjusted mortality rate increased 28.4%, from 9.143 per 100,000 in 1999 to 11.738 in 2024, after peaking at 14.391 in 2021. Segmented log-linear regression identified four temporal phases: 1999-2004 (annual percent change [APC],-1.76%), 2004-2018 (APC, 2.57%), 2018-2021 (APC, 6.54%), and 2021-2024 (APC, −5.98%). Encephalopathy was listed as the underlying cause in only 21.6% of deaths in 2024. Unspecified encephalopathy surged more than 3.6-fold, while anoxic brain injury remained stable. Mortality remained higher in males than females (13.973 versus 9.778 per 100,000), and rates among non-Hispanic Black individuals were 1.90-fold those of non-Hispanic White individuals. Geographically, mortality clustered in the Midwest and South (13.144 and 13.120 per 100,000 in 2024), with persistent state-level dispersion across the study period. COVID-19 accounted for 10.9% of associated deaths in 2021 before falling to 1.4% in 2024. These findings reveal a nonlinear trajectory shaped by diagnostic shifts, pandemic disruption, and persistent demographic and geographic disparities.
Open AccessNational trends, demographic disparities, and phenotypic shifts in encephalopathy-associated mortality in the United States: A CDC WONDER analysis, 1999-2024
Encephalopathy is a lethal manifestation of global cerebral dysfunction spanning hypoxic, metabolic, toxic, and vascular etiologies, yet its population burden is difficult to quantify because it predominantly appears as a contributing rather than underlying cause of death. Here, we analyzed US multiple-cause death records from 1999 through 2024 using harmonized CDC WONDER datasets. A longitudinally consistent core definition of 10 ICD-10 codes identified 953,846 encephalopathy-associated deaths. The national age-adjusted mortality rate increased 28.4%, from 9.143 per 100,000 in 1999 to 11.738 in 2024, after peaking at 14.391 in 2021. Segmented log-linear regression identified four temporal phases: 1999-2004 (annual percent change [APC],-1.76%), 2004-2018 (APC, 2.57%), 2018-2021 (APC, 6.54%), and 2021-2024 (APC, −5.98%). Encephalopathy was listed as the underlying cause in only 21.6% of deaths in 2024. Unspecified encephalopathy surged more than 3.6-fold, while anoxic brain injury remained stable. Mortality remained higher in males than females (13.973 versus 9.778 per 100,000), and rates among non-Hispanic Black individuals were 1.90-fold those of non-Hispanic White individuals. Geographically, mortality clustered in the Midwest and South (13.144 and 13.120 per 100,000 in 2024), with persistent state-level dispersion across the study period. COVID-19 accounted for 10.9% of associated deaths in 2021 before falling to 1.4% in 2024. These findings reveal a nonlinear trajectory shaped by diagnostic shifts, pandemic disruption, and persistent demographic and geographic disparities.
- Open Access
Internal Dose Benchmarking of Acrylamide Exposure and Peripheral Neuropathy Risk: A National Population-Based Validation Study
Background. Acrylamide, a neurotoxicant in heated foods and smoke, is linked to occupational neuropathy, but evidence regarding chronic, low-level population exposure remains limited. We evaluated the association between acrylamide exposure biomarkers and peripheral neuropathy among U.S. adults. Methods. A total of 2,266 NHANES 2003-2004 participants (age >40) were analyzed. Exposure was assessed via hemoglobin adducts (HbAA/HbGA); neuropathy via monofilament testing >1 site). Survey-weighted logistic regression models adjusted for confounders. Sensitivity analyses included cubic splines, diabetes stratification, and multiple imputation. Results. Neuropathy prevalence was 15.5%. In adjusted models, neither adduct was associated with neuropathy (HbAA OR: 0.98, 95% CI: 0.82-1.17; HbGA OR: 0.91, 95% CI: 0.77-1.08). No dose-response gradient was observed. Expected risk factors (age, diabetes) showed strong associations, validating model sensitivity. The null result remained robust across sensitivity analyses, including a stricter outcome definition and multiple imputation (pooled OR: 0.97, 95% CI: 0.83-1.14). Conclusions. Acrylamide adducts were not associated with peripheral neuropathy in this national sample. General population levels (~55-70 pmol/g) lie well below established occupational no-observed-adverse-effect levels (~510 pmol/g) and clinical neuropathy thresholds (~6,000 pmol/g), providing a mechanistically coherent explanation for this null result.
Open AccessInternal Dose Benchmarking of Acrylamide Exposure and Peripheral Neuropathy Risk: A National Population-Based Validation Study
Background. Acrylamide, a neurotoxicant in heated foods and smoke, is linked to occupational neuropathy, but evidence regarding chronic, low-level population exposure remains limited. We evaluated the association between acrylamide exposure biomarkers and peripheral neuropathy among U.S. adults. Methods. A total of 2,266 NHANES 2003-2004 participants (age >40) were analyzed. Exposure was assessed via hemoglobin adducts (HbAA/HbGA); neuropathy via monofilament testing >1 site). Survey-weighted logistic regression models adjusted for confounders. Sensitivity analyses included cubic splines, diabetes stratification, and multiple imputation. Results. Neuropathy prevalence was 15.5%. In adjusted models, neither adduct was associated with neuropathy (HbAA OR: 0.98, 95% CI: 0.82-1.17; HbGA OR: 0.91, 95% CI: 0.77-1.08). No dose-response gradient was observed. Expected risk factors (age, diabetes) showed strong associations, validating model sensitivity. The null result remained robust across sensitivity analyses, including a stricter outcome definition and multiple imputation (pooled OR: 0.97, 95% CI: 0.83-1.14). Conclusions. Acrylamide adducts were not associated with peripheral neuropathy in this national sample. General population levels (~55-70 pmol/g) lie well below established occupational no-observed-adverse-effect levels (~510 pmol/g) and clinical neuropathy thresholds (~6,000 pmol/g), providing a mechanistically coherent explanation for this null result.